Decoding the future of health: How genetic testing at AEON Clinic is redefining longevity Gulf Business
Read the original:
Decoding the future of health: How genetic testing at AEON Clinic is redefining longevity - Gulf Business
Read the original:
Lack of association between common polymorphisms associated with successful aging and longevity in the population of Sardinian Blue Zone - Nature.com
Scientists Unravel the Secrets of 37 Key Genes Linked to Reproductive Health and Longevity SciTechDaily
Continued here:
Scientists Unravel the Secrets of 37 Key Genes Linked to Reproductive Health and Longevity - SciTechDaily
Diet or genetics: Which has a greater impact on lifespan? India Today
See more here:
Diet or genetics: Which has a greater impact on lifespan? - India Today
Dietary restriction or good genes: new study tries to unpick which has a greater impact on lifespan The Conversation
Here is the original post:
Comparison of blood parameters in two genetically different groups of horses for functional longevity in show jumping - Frontiers
Dietary restriction impacts health and lifespan of genetically diverse mice Nature.com
See the original post:
Dietary restriction impacts health and lifespan of genetically diverse mice - Nature.com
Study: Eating Less Could Significantly Improve LifespanIf You Have Good Genes NTD
Link:
Study: Eating Less Could Significantly Improve LifespanIf You Have Good Genes - NTD
New Research Reveals Genetic Tweaks to Boost Oat Nutrition and Longevity India Education Diary
See the original post here:
New Research Reveals Genetic Tweaks to Boost Oat Nutrition and Longevity - India Education Diary
BOSTON and HOUSTON, Dec. 04, 2023 (GLOBE NEWSWIRE) -- imaware, a digital health platform company powering home-testing for healthcare brands, and binx health, a molecular diagnostics and consumer testing company, today announced that imaware has acquired binx health’s at-home consumer testing business. The acquisition will expand imaware’s position in the growing market for home-health testing and expand the number of enterprise clients being serviced by imaware. binx health will retain and continue to grow its point-of-care molecular diagnostics business, which is excluded from the imaware transaction.
View original post here:
imaware acquires binx health’s consumer testing business, becoming a leader in STI health screening
Ms. Alicia Grande, Catalyst's Current CFO, to Retire at the End of 2023
Read the original:
Catalyst Pharmaceuticals Announces Appointment of Michael W. Kalb as Chief Financial Officer and Other Executive Promotions
– CorMedix to advocate for patient safety and infection prevention as part of Leapfrog’s Partners Advisory Committee
Read more:
CorMedix Inc. Announces Partnership With The Leapfrog Group
NEW YORK, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Sunshine Biopharma, Inc. (NASDAQ: “SBFM”) (the “Company”), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals today announced that it has moved its headquarters to New York City. The Company’s Head Office is now located at 1177 Avenue of the Americas, 5th Floor, New York, NY 10036 (Tel: 332-216-1147). The Company will maintain a satellite office at its previous headquarters in Montreal (Canada) at 6500 Trans-Canada Highway, 4th Floor, Pointe-Claire, Quebec, Canada, H9R 0A5 (Tel: 514-426-6161). The Company’s email address (info@sunshinebiopharma.com) and URL (www.sunshinebiopharma.com) have not changed.
Read the original post:
Sunshine Biopharma Moves Principal Office to New York City
Confirmed partial responses without dose-limiting toxicities during dose escalation along with new preclinical data support the opportunity to further enhance efficacy through a novel split daily dosing regimen at higher dose levels of Nana-val
- Independent Data Monitoring Committee (IDMC) Recommended Continuation of Phase 3 REGAL Trial Without Any Modifications -
See the article here:
SELLAS Life Sciences Announces Positive Recommendation from REGAL Independent Data Monitoring Committee of Galinpepimut-S in Acute Myeloid Leukemia
- Pre-NDA Meeting to discuss requirements for a 505(b)(2) NDA submission for IkT-001Pro in up to eight blood and stomach cancer indications -
Read more:
Inhibikase Therapeutics Granted Pre-NDA Meeting with the FDA for IkT-001Pro
Technological advances reduce time and increase efficiency for MDD treatment Technological advances reduce time and increase efficiency for MDD treatment
More here:
NeuroStar TMS Receives Expanded Regulatory Approval in Japan
Holliston, MA, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Harvard Apparatus Regenerative Technology, Inc. (OTCQB: HRGN) (“Harvard Apparatus Regenerative Technology” or the “Company”), a clinical-stage biotechnology company developing the technology to regenerate organs inside the body to treat severe diseases, today announced that it officially executed a Sponsored Research Agreement (SRA) with Hugh Taylor, MD, chair of Obstetrics, Gynecology & Reproductive Sciences at Yale School of Medicine. The program will focus on the use of Harvard Apparatus Regenerative Technology’s cell-based scaffold platform to restore fertility by repairing uterine tissue in a mouse model of uterine damage.
PALO ALTO, Calif., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced that the State of Tennessee added ZTlido® as a preferred agent to the Medicaid Preferred Drug List effective as of October 1, 2023.1 This change has the potential to improve access to ZTlido® for all eligible patients which includes approximately 1,500,000 adult lives between the ages of 19 to 64.1
Continue reading here:
Scilex Holding Company announces the addition of ZTlido® (lidocaine topical system) as a preferred agent to the Medicaid Preferred Drug List (PDL) of...
BRISBANE, CALIFORNIA, Dec. 04, 2023 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager, TriKE® platform, today announced the submission of an Investigational New Drug (IND) application with the US Food and Drug Administration (FDA) for the development of GTB-3650, a 2nd generation nanobody TriKE® for the treatment of patients with CD33+ leukemia, including relapsed/refractory acute myelogenous leukemia (AML) and high-risk myelodysplastic syndrome (MDS).
See more here:
GT Biopharma Announces IND Submission for GTB-3650 for Treatment of CD33+ Leukemia